---
figid: PMC4422447__13069_2015_23_Fig1_HTML
figtitle: Angiotensin II, transforming growth factorB, and Smad signaling pathways
organisms:
- NA
pmcid: PMC4422447
filename: 13069_2015_23_Fig1_HTML.jpg
figlink: /pmc/articles/PMC4422447/figure/Fig1/
number: F1
caption: Angiotensin II, transforming growth factor-β, and Smad signaling pathways.
  Binding of angiotensin II (AngII) to the angiotensin type 1 receptor (AT1) results
  in Smad2 and Smad3 phosphorylation via the ERK/p38/MAPK pathway. Activated Smad2
  and Smad3 complex with Smad4 and translocate into the nucleus resulting in transcription
  of target genes including transforming growth factor-β (TGF-β), procollagen I, procollagen
  III, and fibronectin. AngII-AT1 binding also directly activates TGF-β, which in
  turn activates Smad signaling in a similar manner. The P-Smad2/3-Smad4 complex induces
  transcription of Smad7, which has an inhibitory effect on TGF-β by targeting TGF-β
  receptor I (TGF-βR1) and Smads for ubiquitin-dependent degradation. Smad7 also inhibits
  NF-κB-driven inflammation via induction of the NF-κB inhibitor, IκBα. Conversely,
  activation of the AngII type 2 receptor (AT2) signaling has an inhibitory effect
  on both Smad and MAPK signaling pathways via dephosphorylating actions of phosphotyrosine
  phosphatase and protein phosphatase 2A. This produces antiproliferative and survival-promoting
  effects that oppose AT1-mediated fibrotic changes. Green lines indicate positive
  regulation. Red lines indicate negative regulation. Latent TGF-β binding protein
  (LTBP), TGF-β receptor 2 (TGF-βIIR), thrombospondin-1 (TSP-1), extracellular signal-relate
  kinase (ERK), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB),
  inhibitor of kappa B alpha (IκBα), protein serine/threonine phosphatase 2A (PP2A),
  phosphotyrosine phosphatase (PTP).
papertitle: Modulation of angiotensin II signaling in the prevention of fibrosis.
reftext: Amanda M Murphy, et al. Fibrogenesis Tissue Repair. 2015;8:7.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9544634
figid_alias: PMC4422447__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC4422447__F1
ndex: 3e32c014-deed-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4422447__13069_2015_23_Fig1_HTML.html
  '@type': Dataset
  description: Angiotensin II, transforming growth factor-β, and Smad signaling pathways.
    Binding of angiotensin II (AngII) to the angiotensin type 1 receptor (AT1) results
    in Smad2 and Smad3 phosphorylation via the ERK/p38/MAPK pathway. Activated Smad2
    and Smad3 complex with Smad4 and translocate into the nucleus resulting in transcription
    of target genes including transforming growth factor-β (TGF-β), procollagen I,
    procollagen III, and fibronectin. AngII-AT1 binding also directly activates TGF-β,
    which in turn activates Smad signaling in a similar manner. The P-Smad2/3-Smad4
    complex induces transcription of Smad7, which has an inhibitory effect on TGF-β
    by targeting TGF-β receptor I (TGF-βR1) and Smads for ubiquitin-dependent degradation.
    Smad7 also inhibits NF-κB-driven inflammation via induction of the NF-κB inhibitor,
    IκBα. Conversely, activation of the AngII type 2 receptor (AT2) signaling has
    an inhibitory effect on both Smad and MAPK signaling pathways via dephosphorylating
    actions of phosphotyrosine phosphatase and protein phosphatase 2A. This produces
    antiproliferative and survival-promoting effects that oppose AT1-mediated fibrotic
    changes. Green lines indicate positive regulation. Red lines indicate negative
    regulation. Latent TGF-β binding protein (LTBP), TGF-β receptor 2 (TGF-βIIR),
    thrombospondin-1 (TSP-1), extracellular signal-relate kinase (ERK), nuclear factor
    kappa-light-chain-enhancer of activated B cells (NF-κB), inhibitor of kappa B
    alpha (IκBα), protein serine/threonine phosphatase 2A (PP2A), phosphotyrosine
    phosphatase (PTP).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TGFB1
  - TGFB2
  - TGFB3
  - THBS1
  - ANGPT2
  - VPS51
  - LAP
  - ACP2
  - PICALM
  - LAP3
  - CENPJ
  - PDON2
  - MAP3K7
  - NR2C2
  - MAPK8
  - MAPK9
  - MAPK10
  - PTPA
  - KRAS
  - HRAS
  - NRAS
  - SLC25A3
  - REG1A
  - PTPRU
  - CRK
  - MAPK14
  - MAPK1
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK3
  - SMAD2
  - SMAD3
  - SMAD4
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - NFKB1
  - SMAD7
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - COL6A1
  - COL6A2
  - COL6A3
  - COL6A5
  - COL6A6
  - COL7A1
  - COL8A1
  - COL8A2
  - COL9A1
  - COL9A2
  - COL9A3
  - COL10A1
  - COL11A1
  - COL11A2
  - COL12A1
  - COL13A1
  - COL14A1
  - COL15A1
  - COL16A1
  - COL17A1
  - COL18A1
  - COL19A1
  - COL20A1
  - COL21A1
  - COL22A1
  - COL23A1
  - COL24A1
  - COL25A1
  - COL26A1
  - COL27A1
  - COL28A1
  - COL1A1
  - COL1A2
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - COL5A1
  - COL5A2
  - COL5A3
---
